The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Levodopa‐induced dyskinesias
Abstract
Levodopa‐induced dyskinesias (LID) are common and difficult to treat. This review focuses on three issues related to LID: clinical features, classification and rating, pathophysiology and pathogenesis, and management. The three primary clinical syndromes are OFF‐period dystonia, peak‐dose dyskinesia, and diphasic dyskinesia. Several other forms also occur, making the evaluation and choice of treatment complicated. A core component of the pathophysiology of LID is overactivity of the direct striatal output pathway. This pathway provides a direct GABAergic connection by which the striatum inhibits the output regions of the basal ganglia, i.e., the internal globus pallidus and the substantia nigra pars reticulata. Altering dopaminergic dosing and timing can abate dyskinesias, but usually impact the control of parkinsonism. Putative therapies to reduce the problem of dyskinesias could focus on the glutamatergic, GABAergic, α 2 adrenergic, serotonergic (5HT 1A, 5HT 2A), opioid, histamine H 3, adenosine A 2A receptors, the monoamine transport or cannabinoid CB1 receptors systems. The only currently available drug with an evidence‐based recommendation on efficacy for dyskinesia is amantadine. Therapy goals include the prevention of dyskinesia and treatment of dyskinesias that are troublesome clinically. New rating measures to assess severity and disability related to dyskinesia are in the process of development and clinimetric testing. © 2007 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
A Randomized Trial of Deep-Brain Stimulation for Parkinson's Disease
Deuschl, G., Schade-Brittinger, C., Krack, P., Volkmann, J., Schäfer, H., Bötzel, K., Daniels, C., Deutschländer, A., Dillmann, U., Eisner, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060281 · Cited by 2,944
Krack, P., Batir, A., Van Blercom, N., Chabardes, S., Fraix, V., Ardouin, C., Koudsie, A., Limousin, P. D., Benazzouz, A., LeBas, J. F., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035275 · Cited by 2,249
Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale
Fahn, S. (1987) · Medical Entomology and Zoology · Cited by 2,163
Levodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa000827 · Cited by 1,514
Ahlskog, J. E., & Muenter, M. D. (2001) · Movement Disorders · doi:10.1002/mds.1090 · Cited by 1,454
Subthalamic nucleus deep brain stimulation: Summary and meta-analysis of outcomes
Kleiner-Fisman, G., Herzog, J., Fisman, D. N., Tamma, F., Lyons, K. E., Pahwa, R., Lang, A. E., & Deuschl, G. (2006) · Movement Disorders · doi:10.1002/mds.20962 · Cited by 957
Patient compliance with paper and electronic diaries
Stone, A. A., Shiffman, S., Schwartz, J. E., Broderick, J. E., & Hufford, M. R. (2003) · Controlled Clinical Trials · doi:10.1016/s0197-2456(02)00320-3 · Cited by 910
Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
Holloway, R. G., Shoulson, I., Kieburtz, K. D., McDermott, M., Tariot, P. N., Kamp, C., Day, D., Shinaman, A., Fahn, S., Lang, A. E., et al. (2000) · JAMA · Cited by 798
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A Randomized Controlled Trial
Parkinson Study Group (2000) · JAMA · doi:10.1001/jama.284.15.1931 · Cited by 767
Rascol, O., Brooks, D., Melamed, E., Oertel, W., Poewe, W., Stocchi, F., & Tolosa, E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71083-7 · Cited by 641
Dyskinesias and motor fluctuations in Parkinson's disease
Schrag, A., & Quinn, N. (2000) · Brain · doi:10.1093/brain/123.11.2297 · Cited by 600
Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations
Jankovic, J. (2005) · Movement Disorders · doi:10.1002/mds.20458 · Cited by 547
Impact of the motor complications of Parkinson's disease on the quality of life
Chapuis, S., Ouchchane, L., Metz, O., Gerbaud, L., & Durif, F. (2005) · Movement Disorders · doi:10.1002/mds.20279 · Cited by 521
Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies
Bezard, E., Brotchie, J. M., & Gross, C. E. (2001) · Nature Reviews Neuroscience · doi:10.1038/35086062 · Cited by 503
Self-citationPahwa, R., Factor, S. A., Lyons, K. E., Ondo, W. G., Gronseth, G., Bronte-Stewart, H., Hallett, M., Miyasaki, J., Stevens, J., & Weiner, W. J. (2006) · Neurology · doi:10.1212/01.wnl.0000215250.82576.87 · Cited by 499
Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism
Schrag, A., & Schott, J. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70411-2 · Cited by 384
Goetz, C. G., Poewe, W., Rascol, O., & Sampaio, C. (2005) · Movement Disorders · doi:10.1002/mds.20464 · Cited by 376
Self-citationBurchiel, K. J., Anderson, V. C., Favre, J., & Hammerstad, J. P. (1999) · Neurosurgery · doi:10.1097/00006123-199912000-00024 · Cited by 371
Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, part II
Mouradian, M. M., Junecos, J. L., Fabbrini, G., Schlegel, J., Bartko, J. J., & Chase, T. N. (1988) · Annals of Neurology · doi:10.1002/ana.410240304 · Cited by 360
Self-citationParkinson Study Group (1996) · Annals of Neurology · doi:10.1002/ana.410390107 · Cited by 356
Katzenschlager, R., Hughes, A., Evans, A., Manson, A. J., Hoffman, M., Swinn, L., Watt, H., Bhatia, K., Quinn, N., & Lees, A. J. (2005) · Movement Disorders · doi:10.1002/mds.20276 · Cited by 286
Fluctuations of disability in Parkinson's disease – clinical aspects
Marsden, C. D., Parkes, J. D., & Quinn, N. (1981) · Movement Disorders · doi:10.1016/b978-0-407-02295-9.50012-6 · Cited by 284
Goetz, C. G., Stebbins, G. T., Shale, H. M., Lang, A. E., Chernik, D. A., Chmura, T. A., Ahlskog, J. E., & Dorflinger, E. E. (1994) · Movement Disorders · doi:10.1002/mds.870090403 · Cited by 276
Self-citation(2000) · Annals of Neurology · doi:10.1002/1531-8249(200001)47:1<2::aid-ana2>3.0.co;2-b · Cited by 249
Duration of amantadine benefit on dyskinesia of severe Parkinson's disease.
Thomas, A., Iacono, D., Luciano, A. L., Armellino, K., Iorio, A. D., & ONOFRJ, M. C. (2004) · PubMed Central · Cited by 246
Randomized trial of pallidotomy versus medical therapy for Parkinson's disease
Vitek, J. L., Bakay, R. A. E., Freeman, A., Evatt, M., Green, J., McDonald, W., Haber, M., Barnhart, H., Wahlay, N., Triche, S., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10517 · Cited by 243
Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models
Bibbiani, F., Oh, J. D., & Chase, T. N. (2001) · Neurology · doi:10.1212/wnl.57.10.1829 · Cited by 241
Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology
Marconi, R., Lefebvre‐Caparros, D., Bonnet, A., Vidailhet, M., Dubois, B., & Agid, Y. (1994) · Movement Disorders · doi:10.1002/mds.870090103 · Cited by 237
Comparison of Immediate-Release and Controlled Release Carbidopa/Levodopa in Parkinson’s Disease
Block, G., Liss, C., Reines, S., Irr, J., & Nibbelink, D. (1997) · European Neurology · doi:10.1159/000117399 · Cited by 234
Clozapine improves dyskinesias in Parkinson disease: A double-blind, placebo-controlled study
Durif, F., Debilly, B., Galitzky, M., Morand, D., Viallet, F., Borg, M., Thobois, S., Broussolle, E., & Rascol, O. (2004) · Neurology · doi:10.1212/01.wnl.0000110317.52453.6c · Cited by 224
Advantages of a modified scoring method for the rush video-based tic rating scale
Goetz, C. G., Pappert, E. J., Louis, E. D., Raman, R., & Leurgans, S. (1999) · Movement Disorders · doi:10.1002/1531-8257(199905)14:3<502::aid-mds1020>3.0.co;2-g · Cited by 215
Self-citationPergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study
Oertel, W. H., Wolters, E., Sampaio, C., Gimenez‐Roldan, S., Bergamasco, B., Dujardin, M., Grosset, D. G., Arnold, G., Leenders, K. L., Hundemer, H., et al. (2006) · Movement Disorders · doi:10.1002/mds.20724 · Cited by 210
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys
Konitsiotis, S., Blanchet, P. J., Verhagen, L., Lamers, E., & Chase, T. N. (2000) · Neurology · doi:10.1212/wnl.54.8.1589 · Cited by 201
Zappia, M., Annesi, G., Nicoletti, G., Arabia, G., Annesi, F., Messina, D., Pugliese, P., Spadafora, P., Tarantino, P., Carrideo, S., et al. (2005) · Archives of Neurology · doi:10.1001/archneur.62.4.601 · Cited by 201
Péchevis, M., Clarke, C. E., Vieregge, P., Khoshnood, B., Deschaseaux‐Voinet, C., Berdeaux, G., Ziegler, M., & on behalf of the Trial Study Group (2005) · European Journal of Neurology · doi:10.1111/j.1468-1331.2005.01096.x · Cited by 196
Parkinson's disease home diary: Further validation and implications for clinical trials
Hauser, R. A., Deckers, F., & Lehert, P. (2004) · Movement Disorders · doi:10.1002/mds.20248 · Cited by 194
Nondopaminergic mechanisms in levodopa‐induced dyskinesia
Brotchie, J. M. (2005) · Movement Disorders · doi:10.1002/mds.20612 · Cited by 192
Self-citationFactors Associated With the Development of Motor Fluctuations and Dyskinesias in Parkinson Disease
Hauser, R. A. (2006) · Archives of Neurology · doi:10.1001/archneur.63.12.1756 · Cited by 183
Unilateral pallidotomy in Parkinson's disease: a randomised, single-blind, multicentre trial
de Bie, R. M., de Haan, R. J., Nijssen, P. C., Rutgers, A. W. F., Beute, G. N., Bosch, D. A., Haaxma, R., Schmand, B., Schuurman, P. R., Staal, M. J., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)03556-4 · Cited by 177
Snow, B. J., Macdonald, L., Mcauley, D., & Wallis, W. (2000) · Clinical Neuropharmacology · doi:10.1097/00002826-200003000-00004 · Cited by 174
Levodopa‐dyskinesia incidence by age of Parkinson's disease onset
Kumar, N., Van Gerpen, J. A., Bower, J. H., & Ahlskog, J. E. (2005) · Movement Disorders · doi:10.1002/mds.20360 · Cited by 162
Patterns of dystonia ("I-D-I" and "D-I-D-") in response to l-dopa therapy for Parkinson's disease.
Muenter, M. D., Sharpless, N. S., Tyce, G. M., & Darley, F. L. (1977) · PubMed · Cited by 151
Drug Insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease
Olanow, C., Obeso, J., & Stocchi, F. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0222 · Cited by 150
Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease
Rascol, O., Arnulf, I., Paul, H. P., Brefel‐Courbon, C., Vidailhet, M., Thalamas, C., Bonnet, A. M., Descombes, S., Bejjani, B.-P. W., Fabre, N., et al. (2001) · Movement Disorders · doi:10.1002/mds.1143 · Cited by 149
Stiff person syndrome with eye movement abnormality, myasthenia gravis, and thymoma
Thomas, S. (2004) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.036558 · Cited by 149
van Gerpen, J. A., Kumar, N., Bower, J. H., Weigand, S. D., & Ahlskog, J. E. (2006) · Archives of Neurology · doi:10.1001/archneur.63.2.205 · Cited by 146
Motor fluctuations and dyskinesia in Parkinson's disease
Nutt, J. G. (2001) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(01)00024-4 · Cited by 141
Clinical–Pathological study of levodopa complications
Rajput, A. H., Fenton, M. E., Birdi, S., Macaulay, R. J. B., George, D. H., Rozdilsky, B., Ang, L. C., Senthilselvan, A., & Hornykiewicz, O. (2002) · Movement Disorders · doi:10.1002/mds.10031 · Cited by 127
Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations
Marras, C., Lang, A. E., Krahn, M. D., TOMLINSON, G. A., Naglie, G., & The Parkinson Study Group (2004) · Movement Disorders · doi:10.1002/mds.10642 · Cited by 112
Damiano, A. M., Mordin, M., Willian, M. K., Snyder, C. F., LeWitt, P. A., Reyes, P. F., Richter, R., & Means, E. D. (2000) · Quality of Life Research · doi:10.1023/a:1008928321652 · Cited by 109
Continuous Transdermal Dopaminergic Stimulation in Advanced Parkinson's Disease
Metman, L. V., Gillespie, M., Farmer, C. M., Bibbiani, F., Konitsiotis, S., Morris, M. J., Shill, H. A., Bara‐Jimenez, W., Mouradian, M. M., & Chase, T. N. (2001) · Clinical Neuropharmacology · doi:10.1097/00002826-200105000-00008 · Cited by 100
Onset and End-of-Dose Levodopa-Induced Dyskinesias
Lhermitte, F. (1978) · Archives of Neurology · doi:10.1001/archneur.1978.00500290007002 · Cited by 91
Smith, L. A., Jackson, M. J., Hansard, M. J., Maratos, E. C., & Jenner, P. G. (2003) · Movement Disorders · doi:10.1002/mds.10394 · Cited by 86
Striatal glutamatergic mechanisms and extrapyramidal movement disorders
Chase, T. N., Bibbiani, F., & Oh, J. D. (2003) · Neurotoxicity Research · doi:10.1007/bf03033378 · Cited by 78
Jim�nez-Jim�nez, F. J., Puertas, I., & de Toledo, M. (2004) · CNS Drugs · doi:10.2165/00023210-200418020-00003 · Cited by 78
Quetiapine Attenuates Levodopa-Induced Motor Complications in Rodent and Primate Parkinsonian Models
Oh, J. D., Bibbiani, F., & Chase, T. N. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.8009 · Cited by 71
Levodopa Infusion Therapy in Parkinson Disease: State of the Art in 2004
Nyholm, D., & Aquilonius, S. (2004) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000144041.28224.b7 · Cited by 66
Motor fluctuations in Parkinson’s disease
Denny, A. P., & Behari, M. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00052-0 · Cited by 57
Inhibition of catechol‐O‐methyltransferase contributes to more stable levodopa plasma levels
Müller, T. H., Erdmann, C., Muhlack, S., Bremen, D., Przuntek, H., & Woitalla, D. (2005) · Movement Disorders · doi:10.1002/mds.20717 · Cited by 54
Respiratory dyskinesia in Parkinson's disease
Jankovic, J. J., & Nour, F. (1986) · Neurology · doi:10.1212/wnl.36.2.303-b · Cited by 43
Rating scales for dyskinesias in Parkinson's disease.
Cg, G. (1999) · PubMed · Cited by 42
Corticomuscular coherence is increased in the small postural tremor of Parkinson's disease
Caviness, J. N., Shill, H. A., Sabbagh, M. N., Evidente, V. G. H., Hernández‐Davó, J. L., & Adler, C. H. (2005) · Movement Disorders · doi:10.1002/mds.20743 · Cited by 39
Drugs in development for Parkinson's disease: an update.
Johnston, T. H., & Brotchie, J. M. (2006) · PubMed · Cited by 36
Self-citationMotor fluctuations in Parkinson's disease
Kikuchi, S. (2007) · Journal of Neurology · doi:10.1007/s00415-007-5006-6 · Cited by 32
Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations
Widnell, K. L., & Comella, C. L. (2005) · Movement Disorders · doi:10.1002/mds.20461 · Cited by 30
Levodopa‐induced ocular dyskinesias in Parkinson's disease
Linazasoro, G., Blercom, N. V., Lasa, A., Indakoetxea, B., & Ruiz, J. (2002) · Movement Disorders · doi:10.1002/mds.10017 · Cited by 28
Role of surgery in the treatment of motor complications
Metman, L. V., & O’Leary, S. T. (2005) · Movement Disorders · doi:10.1002/mds.20480 · Cited by 26
Drug Insight: new drugs in development for Parkinson's disease
Colosimo, C., Fabbrini, G., & Berardelli, A. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0340 · Cited by 16
Self-citation
Cited by
Parkinson’s Disease in Women and Men: What’s the Difference?
Cerri, S., Mus, L., & Blandini, F. (2019) · Journal of Parkinson’s Disease · doi:10.3233/jpd-191683 · Cited by 800
Molecular mechanisms of L-DOPA-induced dyskinesia
Jenner, P. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2471 · Cited by 523
Priorities in Parkinson's disease research
Meissner, W. G., Frasier, M., Gasser, T., Goetz, C. G., Lozano, A., Piccini, P., Obeso, J. A., Rascol, O., Schapira, A., Voon, V., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3430 · Cited by 436
Self-citationNMDA receptors in clinical neurology: excitatory times ahead
Kalia, L. V., Kalia, S. K., & Salter, M. W. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70165-0 · Cited by 415
Voon, V., Fernagut, P.-O., Wickens, J., Baunez, C., Rodriguez, M., Pavon, N., Juncos, J. L., Obeso, J. A., & Bezard, E. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70287-x · Cited by 335
Metadata
- Authors
- Fabbrini, G., Brotchie, J. M., Grandas, F., Nomoto, M., & Goetz, C. G.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2007-04-11
- Volume
- 22
- Issue
- 10
- Pages
- 1379-1389
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2121928725
- Cited by
- 464
- References
- 72
- FWCI
- 17.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.